Betty S. Pace, MD '81, GME '84
Keynote Presentation: The Road Less Traveled – A Dream Come True
- Medical College of Georgia at Augusta University
Dr. Betty Pace is a Professor of Pediatrics and Francis J. Tedesco Distinguished Chair of Pediatric Hematology/Oncology at Augusta University. Dr. Pace received her MD degree from the Medical College of Wisconsin, completed Pediatric Residency at the Milwaukee Children’s Hospital, and then trained in Pediatric Hematology/Oncology at the University of Colorado Health Sciences Center in Denver, Colorado. Subsequently, she joined the laboratory of Dr. George Stamatoyannopoulos, at the University of Washington to complete a postdoctoral fellowship (1990-1994). Dr. Pace acquired invaluable molecular biology/bench research skills and mentoring during fellowship that established her career trajectory as a molecular hematologist. Currently, Dr. Pace provides leadership for a NIH-funded basic/translational research laboratory, focused on studies related to globin gene regulation and the discovery of drugs, which induce fetal hemoglobin for treatment of sickle cell disease. She currently has a novel agent benserazide in clinical trial. In 2010, Dr. Pace joined the faculty at Augusta University in the Department of Pediatrics. She served as Director of the Pediatric Comprehensive Sickle Cell Program until 2021, providing subspecialty medical services for over 700 children with sickle cell disease. Parallel her research efforts, since 1994, Dr. Pace has trained over 100 young scientists at the high school through junior faculty levels. In addition, she directs a NHLBI-funded training opportunity, Program to Increase Diversity for Individuals Engaged in Health-Related Research (PRIDE). As of 2021, over 102 junior faculty members from 50 institutions have complete the PRIDE program to expand diversity of the US biomedical science workforce. During our discussion we will discuss my successes and failures along the way to achieving my dream to become a NIH-funded independent investigator treating sickle cell disease.